R

Roche

Global pharmaceuticals and diagnostics company

Principal/Senior Principal Toxicologist

Full-TimeUpdated on 10/14/2026
No salary listed
Senior, Expert
PhD
Shanghai, China
Remote
Biology & Biotech

About the job

Requirements
  • A Ph.D. in Toxicology or a related life sciences discipline, with postdoctoral training or equivalent research experience, and a minimum of 8 years of relevant experience in the pharmaceutical, biotechnology, or CRO industry supporting nonclinical safety and translational toxicology across drug discovery and development.
  • Demonstrated expertise in the design, scientific oversight, and interpretation of a broad range of exploratory and GLP nonclinical toxicology studies.
  • Extensive experience managing outsourced toxicology programs and CRO partnerships to ensure high-quality study execution, regulatory compliance, and timely delivery.
  • Proven experience supporting drug discovery and development programs, including the development of nonclinical safety strategies and regulatory submissions, and experience with China regulatory requirements and interactions with NMPA/CDE.
  • A demonstrated track record of scientific impact, evidenced by significant contributions to project advancement, regulatory success, and influence within the organization and the broader scientific community.
  • Strong decision-making, complex problem-solving, critical data analysis, and benefit–risk assessment.
  • Proven ability to lead and influence cross-functional teams in a highly matrixed global environment, build productive collaborations across disciplines and regions, and effectively communicate complex scientific concepts to project teams, governance committees, senior leadership, and regulatory agencies.
  • Fluency in both English and Mandarin, with excellent written and verbal communication skills.
Responsibilities
  • Serve as the China subject matter expert for translational safety and China regulatory requirements supporting China development programs in collaboration with gRED Translational Safety colleagues.
  • Partner closely with gRED project toxicologists to optimize safety strategies for China development, registration, and lifecycle management.
  • Build productive scientific relationships with China regulatory authorities, including NMPA/CDE, and CRO partners.
  • Provide onsite technical oversight of toxicology studies conducted at CROs in China and other countries in Asia.
  • Serve as the Translational Safety lead for Asia Partnering and participate in due diligence activities with potential China partners.
  • Represent Translational Safety on China governance committees and cross-functional development teams as needed.
  • Incorporate innovative approaches, including Weight of Evidence and New Approach Methodologies, into nonclinical safety assessment.
  • Lead the nonclinical safety assessment of gRED therapeutics by synthesizing existing evidence and investigating toxicologic activity, strategically planning, and designing, implementing, and supervising toxicology studies to support program advancement.
  • Design and implement translational safety strategies to support program advancement and decision-making.
  • Investigate mechanisms of toxicity.
  • Proactively manage potential safety liabilities and communicate their impact to teams and governance committees.
  • Collaborate with pathologists, study operations professionals, pharmacokineticists, and pharmaceutics to create streamlined, innovative translational safety programs for Genentech drug candidates and author regulatory documents.
  • Collaborate with predictive toxicologists to incorporate New Approach Methodologies, including in silico and in vitro models, into safety strategies.
  • Leverage literature independently to develop and optimize evidence-based arguments supporting data interpretation or experimental approaches.
  • Partner with colleagues in Roche's China Innovation Center on nonclinical safety strategies, regulatory interactions, and CRO oversight.
  • Conduct due diligence reviews of potential partnering programs.
  • Participate in and lead interdisciplinary project teams.
  • Represent Genentech/Roche in meetings with regulatory authorities as needed.
  • Provide functional-area mentorship and leadership within Translational Safety.
Desired Qualifications
  • Knowledge of emerging New Approach Methodologies is preferred.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.